Endonovo Therapeutics Inc (OTCMKTS:ENDV), a leading biotechnology company with the prime focus on developing bio-electromagnetic products having anti-inflammatory properties, intends to start next phase of testing. As per the reports, the company has expressed its intentions to start pre-clinical testing of electroceutical technology.
With the help of this electroceutical technology, doctors can easily treat chronic and acute inflammatory liver pathologies. These pathologies are comprised of human cirrhotic liver disease and nonalcoholic steatohepatitis.
Insights On The Matter:
According to a recent estimation of American Liver Foundation, over 30% of the United States population is suffering from non-alcoholic fatty liver diseases. Nonalcoholic steatohepatitis or NASH is a different type of cellular damage and liver inflammation, which is caused by the accumulation of fat in the liver. It’s found in those mid-aged people who take little or no alcohol and have problems like obese and overweight.
More than 20% of those people who are suffering from NASH go on to face scarring of cirrhosis and liver if not paid any attention. Most of the acute cases require a liver transplant, failure to which can cause one his life. As of now, there is no approved therapy that can be used to cure NASH. Based on the present scenario, there are not more than a few therapies that will get approved over the next couple of years or so.
The senior management of Endonovo Therapeutics Inc (OTCMKTS:ENDV) is confident about the current progress of pre-clinical testing. According to Alan Collier, the proprietary electroceutical technology of the company comes with a great potential and is capable of addressing various issues that aren’t yet resolved. The company has planned to initiate pre-clinical testing of this technology and hopes that things will continue to fall in the right place. Further updates will be shared with shareholders in the future, as and when something new happens.